Several guidelines suggest investigating the incidence and prevalence of vaccine-preventable infections in adult patients with autoimmune or inflammatory diseases; consequently, the effect and safe-ty issues of vaccination are under careful examination. Moreover, immunosup-pression and immunodeficiency were con-traindications for the previously available vaccine in the past years, thus live zoster vaccine was originally recommended for immunocompetent adults aged ≥50 years, leading to an unmet need for vaccination against HZ in immunocompromised adults. Considering all these efforts and the current pandemic challenge, we be-lieve that now more than ever we are asked to quickly detect potential adverse events, even extremely rare and mild ones, and to face them, in order to support the robust pharmacovigilance campaign for SARS-CoV2 vaccination.

Reply to: “Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab” by Josef Finsterer

Maranini, B.
Primo
Writing – Original Draft Preparation
;
Ciancio, G.
Secondo
Methodology
;
Cultrera, R.
Penultimo
Investigation
;
Govoni, M.
Ultimo
Writing – Review & Editing
2022

Abstract

Several guidelines suggest investigating the incidence and prevalence of vaccine-preventable infections in adult patients with autoimmune or inflammatory diseases; consequently, the effect and safe-ty issues of vaccination are under careful examination. Moreover, immunosup-pression and immunodeficiency were con-traindications for the previously available vaccine in the past years, thus live zoster vaccine was originally recommended for immunocompetent adults aged ≥50 years, leading to an unmet need for vaccination against HZ in immunocompromised adults. Considering all these efforts and the current pandemic challenge, we be-lieve that now more than ever we are asked to quickly detect potential adverse events, even extremely rare and mild ones, and to face them, in order to support the robust pharmacovigilance campaign for SARS-CoV2 vaccination.
2022
Maranini, B.; Ciancio, G.; Cultrera, R.; Govoni, M.
File in questo prodotto:
File Dimensione Formato  
REUMA1_ING_07_Maranini_1482_LETTER_046-048.pdf

accesso aperto

Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 546.19 kB
Formato Adobe PDF
546.19 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2485516
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact